Orchestra BioMed Holdings (OBIO) Operating Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Operating Margin of 20069.09% for Q1 2026, down 1788925.0% year-over-year from N/an in Q1 2025, and down 91967.94% quarter-over-quarter from 21.85% in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Operating Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Operating Margin for 5 consecutive years, with 20069.09% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin fell 1788925.0% year-over-year to 20069.09%; the TTM figure through Mar 2026 stood at 167.96% (up 221593.0% YoY), while the FY2025 annual figure was 154.73%, up 228276.0% from the prior year.
- Operating Margin retreated to 20069.09% in Q1 2026 per OBIO's latest filing, from 21.85% in the prior quarter.
- Across five years, Operating Margin topped out at 21.85% in Q4 2025 and bottomed at 20069.09% in Q1 2026.
- Historically, Operating Margin has averaged 3207.6% across 5 years, with a median of 2166.97% in 2024.
- Annual changes were most pronounced in 2025 — Operating Margin jumped 661355 bps — and 2026, when it slumped 1788925 bps.
- Orchestra BioMed Holdings' Operating Margin stood at 891.02% in 2022, then plunged by 435 bps to 4763.74% in 2023, then tumbled by 38 bps to 6591.7% in 2024, then surged by 100 bps to 21.85% in 2025, then plunged by 91968 bps to 20069.09% in 2026.
- Business Quant data shows OBIO's Operating Margin at 20069.09% in Q1 2026, 21.85% in Q4 2025, and 2359.23% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | -25,404.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25,404.55% |
| Mar 31, 2026 | -20,069.09% |
| Dec 31, 2025 | 21.85% |
| Sep 30, 2025 | -2,359.23% |
| Jun 30, 2025 | -2,311.84% |
| Mar 31, 2025 | -2,179.84% |
| Dec 31, 2024 | -6,591.70% |
| Sep 30, 2024 | -1,655.72% |
| Jun 30, 2024 | -2,166.97% |
| Mar 31, 2024 | -2,326.29% |
| Dec 31, 2023 | -4,763.74% |
| Sep 30, 2023 | -3,466.35% |
| Jun 30, 2023 | -1,415.96% |
| Mar 31, 2023 | -991.84% |
| Dec 31, 2022 | -891.02% |
| Sep 30, 2022 | -865.61% |
| Jun 30, 2022 | -1,903.74% |
| Mar 31, 2022 | -592.15% |